These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 36607502)

  • 1. COVID-19 vaccines adverse events: potential molecular mechanisms.
    Lamprinou M; Sachinidis A; Stamoula E; Vavilis T; Papazisis G
    Immunol Res; 2023 Jun; 71(3):356-372. PubMed ID: 36607502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis.
    Chu DK; Abrams EM; Golden DBK; Blumenthal KG; Wolfson AR; Stone CA; Krantz MS; Shaker M; Greenhawt M
    JAMA Intern Med; 2022 Apr; 182(4):376-385. PubMed ID: 35188528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.
    Abukhalil AD; Shatat SS; Abushehadeh RR; Al-Shami N; Naseef HA; Rabba A
    BMC Infect Dis; 2023 Jan; 23(1):5. PubMed ID: 36604613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
    Walker JL; Schultze A; Tazare J; Tamborska A; Singh B; Donegan K; Stowe J; Morton CE; Hulme WJ; Curtis HJ; Williamson EJ; Mehrkar A; Eggo RM; Rentsch CT; Mathur R; Bacon S; Walker AJ; Davy S; Evans D; Inglesby P; Hickman G; MacKenna B; Tomlinson L; Ca Green A; Fisher L; Cockburn J; Parry J; Hester F; Harper S; Bates C; Evans SJ; Solomon T; Andrews NJ; Douglas IJ; Goldacre B; Smeeth L; McDonald HI
    Vaccine; 2022 Jul; 40(32):4479-4487. PubMed ID: 35715350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records.
    Niesen MJM; Pawlowski C; O'Horo JC; Challener DW; Silvert E; Donadio G; Lenehan PJ; Virk A; Swift MD; Speicher LL; Gordon JE; Geyer HL; Halamka JD; Venkatakrishnan AJ; Soundararajan V; Badley AD
    JAMA Netw Open; 2022 Apr; 5(4):e227038. PubMed ID: 35420661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.
    Jaycox JR; Lucas C; Yildirim I; Dai Y; Wang EY; Monteiro V; Lord S; Carlin J; Kita M; Buckner JH; Ma S; Campbell M; Ko A; Omer S; Lucas CL; Speake C; Iwasaki A; Ring AM
    Nat Commun; 2023 Mar; 14(1):1299. PubMed ID: 36894554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of hematologic adverse events reported to a national surveillance system following COVID-19 bivalent booster vaccination.
    Jacobs JW; Booth GS; Adkins BD
    Ann Hematol; 2023 Apr; 102(4):955-959. PubMed ID: 36795118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.
    Li X; Raventós B; Roel E; Pistillo A; Martinez-Hernandez E; Delmestri A; Reyes C; Strauss V; Prieto-Alhambra D; Burn E; Duarte-Salles T
    BMJ; 2022 Mar; 376():e068373. PubMed ID: 35296468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaphylaxis to SARS-CoV-2 Vaccines in the Setting of a Nationwide Passive Epidemiological Surveillance Program.
    Toledo-Salinas C; Scheffler-Mendoza SC; Castano-Jaramillo LM; Ortega-Martell JA; Del Rio-Navarro BE; Santibáñez-Copado AM; Díaz-Ortega JL; Baptista-Rosas R; Sánchez-Novoa P; García-Grimshaw M; Valdés-Ferrer SI; Reyes-Terán G; Mendoza-Hernández DA
    J Clin Immunol; 2022 Nov; 42(8):1593-1599. PubMed ID: 35976470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 Vaccination in Korea.
    Park WB; Hwang YH; Cheong HJ
    Infect Chemother; 2023 Mar; 55(1):135-149. PubMed ID: 37021429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of SARS-CoV-2-Specific Antibodies in Human Breast Milk and Their Neutralizing Capacity after COVID-19 Vaccination: A Systematic Review.
    Nicolaidou V; Georgiou R; Christofidou M; Felekkis K; Pieri M; Papaneophytou C
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis.
    Stefanou MI; Palaiodimou L; Theodorou A; Christodoulou MV; Tzartos JS; Tzanetakos D; Kitsos D; Chondrogianni M; Zouvelou V; Dardiotis E; Tzavellas E; Syrigou E; Benetou V; Paraskevas GP; Tsiodras S; Tsivgoulis G; Giannopoulos S
    Mult Scler; 2023 Apr; 29(4-5):585-594. PubMed ID: 36722184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
    Nasreen S; Calzavara A; Buchan SA; Thampi N; Johnson C; Wilson SE; Kwong JC;
    Vaccine; 2022 May; 40(24):3305-3312. PubMed ID: 35527057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of COVID-19 vaccines, preventive strategies, and patient management.
    Prabhu MM; Palaian S; Ansari M
    Expert Rev Vaccines; 2022 Aug; 21(8):1087-1095. PubMed ID: 35559718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guillain-Barré syndrome and COVID-19 vaccines: focus on adenoviral vectors.
    Rzymski P
    Front Immunol; 2023; 14():1183258. PubMed ID: 37180147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
    Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
    Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebral venous sinus thrombosis after COVID-19 vaccination and congenital deficiency of coagulation factors: Is there a correlation?
    Mele F; Tafuri S; Stefanizzi P; D Amati A; Calvano M; Leonardelli M; Macorano E; Duma S; De Gabriele G; Introna F; De Donno A
    Hum Vaccin Immunother; 2022 Nov; 18(6):2095166. PubMed ID: 35895937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine.
    Abi Zeid Daou C; Natout MA; El Hadi N
    J Med Virol; 2021 Oct; 93(10):6027-6029. PubMed ID: 34050949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.